deltatrials
Completed PHASE1 INTERVENTIONAL 3-arm NCT03583606

A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)

A Systems Biology Phase 1 Evaluation of the Safety, Reactogenicity, and Immunogenicity of Chimpanzee Adenovirus Type 3- Vectored Zaire Ebolavirus (ChAd3-EBO-Z) and Modified Vaccinia Ankara- Vectored Multivalent Filovirus (MVA-BN(R)-Filo) Vaccine Candidates

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Ebola Disease Immunisation
Interventions ChAd3-EBO-Z MVA Multi-Filo Ebola Vaccine Placebo
Updated 18 times since 2018 Last updated: Jul 17, 2025 Started: Nov 12, 2018 Primary completion: Jan 14, 2020 Completion: Jan 14, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Ebola Disease and Immunisation, this trial is completed. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 18 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Nov 2019 · 8 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Apr 2024 · 31 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshot~Aug 2025 – present · 11 months · monthly snapshot

Change History

18 versions recorded

  1. Aug 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Aug 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Apr 2024 — Jul 2024 [monthly]

    Completed PHASE1

  5. Sep 2021 — Apr 2024 [monthly]

    Completed PHASE1

▶ Show 13 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE1

  2. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE1

  3. Apr 2020 — Aug 2020 [monthly]

    Completed PHASE1

    Status: Recruiting → Completed

  4. Feb 2020 — Apr 2020 [monthly]

    Recruiting PHASE1

  5. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE1

  6. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  7. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE1

  8. Mar 2019 — Nov 2019 [monthly]

    Recruiting PHASE1

  9. Jan 2019 — Mar 2019 [monthly]

    Recruiting PHASE1

  10. Nov 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  11. Oct 2018 — Nov 2018 [monthly]

    Not Yet Recruiting PHASE1

  12. Sep 2018 — Oct 2018 [monthly]

    Not Yet Recruiting PHASE1

  13. Aug 2018 — Sep 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations